The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Optimal perioperative therapy for incidental gallbladder cancer (OPT-IN): A randomized phase II/III trial—ECOG-ACRIN EA2197.
 
Shishir K. Maithel
Research Funding - Celgene
 
Sung Chul Hong
No Relationships to Disclose
 
Cecilia Grace Ethun
No Relationships to Disclose
 
Cristina R. Ferrone
No Relationships to Disclose
 
Flavio G. Rocha
Consulting or Advisory Role - Medtronic
Research Funding - Gunze
Travel, Accommodations, Expenses - Lynx Group
 
Charles A. Staley
No Relationships to Disclose
 
Peter J. O'Dwyer
Research Funding - Amgen (Inst); Array BioPharma (Inst); BBI Healthcare (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Five Prime Therapeutics (Inst); Forty Seven (Inst); Genentech (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); Lilly/ImClone (Inst); Minneamrita Therapeutics (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Syndax (Inst); Syndax (Inst); Syndax (Inst); Syndax (Inst); syndax (Inst); Taiho Pharmaceutical (Inst)
Expert Testimony - Dai-ichi Sankyo